NRG1 and neoplasm: HER2+ EVs have been shown to be enriched for tumour cell proliferation proteins (36) and their release has been shown to be modulated by growth factors in the surrounding microenvironment such as EGF and heregulin, two of the known HER2 receptor-activating ligands (36), providing some insights into the observed differences.